Acute Coronary Syndrome
Conditions
Keywords
immunoglobulin G
Brief summary
The aim of this study is to investigate the changes in glycopeptides of serum immunoglobulin G in patients with acute myocardial infarction and the relationships between its change and prognosis.
Detailed description
Immunoglobin G (IgG), a highly abundant glycoprotein in serum, is known to participate in blood immune responses.It has been an increasing interest in the analysis of the abnormal glycosylation of human lgG in healthy and disease states, such as autoimmune diseases and cancer.However, there is few relevant studies about the changes in glycopeptides of serum immunoglobulin G in patients with acute myocardial infarction. This study was performed for the frst timeto assess the quantitative changes of serum IgG glycosylation in patients with acute myocardial infarction and the relationships between its change and prognosis.
Interventions
DIAGNOSTIC_TESTQuantitative measurements the changes of IgG glycosylation
Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
Sponsors
Dalian Institute of Chemical Physics, Chinese Academy of Sciences , Dalian
The First Affiliated Hospital of Dalian Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
\- diagnosed as STEMI. * with left ventricular ejection fraction（LVEF）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked
Exclusion criteria
* complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent refusal to sign the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum quantitative determination of lgG | 12 months | Quantitative measurements the changes of serum IgG glycosylation by HPLC-MRM |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relationship between the serum hs-CRP and the quantitative level of lgG glycopeptides in peripheral blood. | 12 months | correlation between the serum hs-CRP and lgG |
| MACEs during 12-month follow-up | 12 months | Association of quantitative level of lgG with prognosis |
| The changes of LVEF in two groups | 12 months | Association of quantitative level of lgG with the changes of cardiac function |
Countries
China
Outcome results
None listed